Cervical Cancer Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies including Regeneron Pharmaceuticals, Zeria Pharmaceutical, Advaxis, AstraZeneca & Others | DelveInsight

October 14 20:08 2021
Cervical Cancer Market: Industry Analysis, Epidemiology, Treatment, Therapies and Key Companies including Regeneron Pharmaceuticals, Zeria Pharmaceutical, Advaxis, AstraZeneca & Others | DelveInsight
Cervical Cancer Market

Cervical Cancer occurs in the cells of the cervix and usually originates in the transformation zone of the cervix, and spreads to regional lymph nodes with parametrial invasion also common.

Most cases of cervical cancer are caused by infection with human papillomavirus (HPV). Apart from HPV, other factors that can also increase the risk include: human immunodeficiency virus (HIV), chlamydia, smoking, obesity, family history of cervical cancer, diet low in fruits and vegetables, taking birth control pills, and having three full-term pregnancies.

 

DelveInsight’s “Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of the Cervical Cancer Market Report:

  • The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • In the 7MM, the United States is the major contributor to the cervical cancer market revenue in 2020, and the region is expected to hold its position in the upcoming years.
  • Key companies propelling the market size include Regeneron, AstraZeneca, Lovance, Zeria Pharmaceutical, Seattle Genetics/Genmab, Agenus Bio, Roche, Akeso Biopharma and Vaccibody/Roche, and among others.
  • Launch of cervical cancer pipeline therapies, including Cemiplimab (Regeneron), Durvalumab (AstraZeneca), LN-145 (Iovance), Z-100 (Zeria Pharmaceutical), Tisotumab vedotin (Seattle Genetics/Genmab) in the next decade is expected to propel the market growth.

 

 

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cervical-cancer-market

 

“As per WHO estimates, Cervical Cancer is the fourth most common cancer in women.”

 

Clinical presentation depends mainly on the location and extent of disease. Precancerous changes or very early stage disease are usually asymptomatic and are detected on a cervical smear. Symptoms usually appear when the tumour causes spontaneous or contact bleeding, or pain if lymph nodes are involved.

All women are at risk for cervical cancer. It occurs most often in women over age 30. There’s more than one kind of cervical cancer.

  • Squamous cell carcinoma-This forms in the lining of cervix. It’s found in up to 90% of cases.
  • Adenocarcinoma-This forms in the cells that produce mucus.
  • Mixed carcinoma-This has features of the two other types.

DelveInsight estimated that cervical cancer is most often diagnosed in women between the ages of 35 and 44, with the average age at diagnosis being 50. The late diagnosis in women is a consequence of a lack of vaccination and screening in women in the early stages of their lives.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cervical-cancer-market

 

Some of the Cervical Cancer Companies are:

  • Regeneron Pharmaceuticals
  • Zeria Pharmaceutical
  • Advaxis
  • AstraZeneca
  • Immunitor
  • And Many Others

 

Cervical cancer Therapies Covered:

  • Libtayo
  • Z-100
  • ADXS11–001
  • IMFINZ
  • V3-Cervix
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cervical-cancer-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Cervical Cancer

3. Competitive Intelligence Analysis for Cervical Cancer

4. Cervical Cancer: Market Overview at a Glance

5. Cervical Cancer: Disease Background and Overview

6. Patient Journey

7. Cervical Cancer Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Cervical Cancer Treatment

11. Marketed Products

12. Emerging Therapies

13. Cervical Cancer: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Cervical Cancer

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cervical-cancer-market